The Alzheimer’s drug Amyvid received FDA approval for a narrower indication than the sponsors originally wanted. The limited indication got the imaging agent to market, but now Amyvid faces another challenge on the reimbursement front.
The initial result wasn’t what Eli Lilly & Co. and its development partner Avid Radiopharmaceuticals Inc. wanted for their potential Alzheimer’s diagnostic agent Amyvid (florbetapir) going into the panel meeting.
The Food & Drug Administration’s Peripheral & Central Nervous System Drugs Advisory Committee voted 13-3 against immediate approval of the...
Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.
